Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cantabio to develop small-molecule chaperones of Abeta peptide
July 2016
SHARING OPTIONS:

PALO ALTO, Calif.—Cantabio Pharmaceuticals Inc. recently announced a new preclinical therapeutic program for Alzheimer’s disease which it is pursuing through its drug discovery partnership with NovAliX. This program is aimed at the development of small-molecule chaperones that stabilize the Abeta peptide, the aggregation of which is considered to be a key element in the onset and progression of Alzheimer’s disease.
 
“We are delighted to announce this exciting program, which fits in well with Cantabio’s existing portfolio of candidates and further demonstrates our innovative pharmacological chaperone-based drug discovery approach in the field of Alzheimer’s, Parkinson’s and related diseases,” said Cantabio CEO Dr. Gergely Toth. “Our collaboration with NovAliX has been highly productive and has helped us to develop novel therapeutic candidates using their unique high-throughput SPR-WORM screen. NovAliX has always been very supportive of our approach and vision; we look forward to continuing to work with them as our industrial partner in drug discovery and to continue to develop candidate therapies in this exciting and highly promising area.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.